Compare Ishares Msci Brazil ETF (EWZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $42.19 (market cap $13.14B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Ishares Msci Brazil ETF is far larger — about 2.7× Travere Therapeutics Inc. Common Stock's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWZ | TVTX | |
|---|---|---|
Market Cap | $13.14B | $4.88B |
Volume | 52,443,793 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $67.52 |
52-Week Low | $29.24 | $26.79 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% today, with a bullish technical signal driven by moving averages but showing overbought RSI levels. The ETF is attracting significant attention due to Brazil's upcoming October election, with institutional investors accumulating positions through call options. Recent news highlights EWZ as a diversification tool against U.S. tech concentration and potential beneficiary of Brazilian economic policies.
The outlook for EWZ hinges on Brazil's political election outcome and commodity trends, offering asymmetric upside but facing currency and political volatility risks. Wall Street positioning suggests optimism, though investors must weigh the ETF's higher expense ratio against alternatives like FLBR for Brazilian exposure.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
